Rapid Identity and Quantity CQA Test for Multivalent mRNA Drug Product Formulations

The COVID-19 pandemic highlighted mRNA as a promising platform for vaccines and therapeutics. Many of the analytical tools used to characterize the critical quality attributes of mRNA are inherently singleplex and are not necessarily optimal from a labor and cost perspective. Here, we demonstrate th...

Descripción completa

Detalles Bibliográficos
Autores principales: Gao, Rachel Y., Riley, Christine M., Toth, Evan, Blair, Rebecca H., Gerold, Megan N., McCormick, Caitlin, Taylor, Amber W., Hu, Tianjing, Rowlen, Kathy L., Dawson, Erica D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9612012/
https://www.ncbi.nlm.nih.gov/pubmed/36298569
http://dx.doi.org/10.3390/vaccines10101704

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9612012/
https://www.ncbi.nlm.nih.gov/pubmed/36298569
http://dx.doi.org/10.3390/vaccines10101704

Ejemplares similares